The purpose of the study is to find out if TGD001 is safe and well-tolerated in people who have had an acute ischemic stroke. The study will also look at whether TGD001 might be helpful in treating this condition. The study is divided into two parts. In the first part, different doses of TGD001 will be tested to find the best dose to use. In the second part, participants will be randomly assigned to receive either TGD001 or placebo, and neither the participants nor the doctors will know which treatment is being given. The study will include people who either have a procedure called endovascular thrombectomy, which is a method to remove blood clots from blood vessels in the brain, or people who do not receive this procedure or the usual clot-dissolving treatment given through a vein.

During the study, doctors will closely monitor participants for any side effects or problems that might occur, particularly bleeding in the brain. They will also check how well participants are doing after their stroke. The study will help researchers understand whether TGD001 could be a useful treatment option for people who have had an acute ischemic stroke.

The purpose of this study is to find out whether giving Tenecteplase directly into the brain’s blood vessel after successful removal of the clot leads to better recovery compared to not giving this additional treatment. The study will measure success by looking at how well patients can function in their daily lives three months after the stroke, specifically checking if they have little to no disability. During the study, patients will first undergo a procedure to remove the blood clot from their brain using mechanical methods. If this procedure successfully reopens the blocked blood vessel, patients will then receive either the clot-dissolving medication or placebo injected directly into the artery in the brain.

The study will follow patients for 90 days after treatment to assess their recovery and ability to perform daily activities. The treatment must be given within 24 hours from when the stroke symptoms began or from when the patient was last known to be well. Patients enrolled in this study will have experienced a stroke caused by a blockage in one of the major blood vessels supplying the front part of the brain, and they must have had successful reopening of this vessel during the mechanical clot removal procedure.

Patients in the study will be divided into different groups. Some groups will receive combinations of the study medications along with their standard care, while another group will receive only standard care. The medications will be given in different forms, including injections under the skin, injections into a vein, and liquids taken by mouth. Treatment will start within 36 hours after stroke symptoms begin and will continue for a certain period. During the study, patients will have regular check-ups and tests to see how they are doing.

The study will use brain imaging tests like CT scans and MRI to look at the brain and check for any bleeding or changes in the damaged area. Doctors will also measure how well patients can perform daily activities and check their stroke symptoms using special scoring systems. Blood tests will be done to measure medication levels and other substances in the blood. The study will also check for side effects, including whether patients develop depression, and will monitor overall safety throughout the treatment period.

The study examines the use of Cangrelor, given through an intravenous line, along with acetylsalicylic acid and clopidogrel. These medications help prevent blood clots from forming. The main purpose is to evaluate if Cangrelor is safe and effective when used during procedures to remove blood clots and place stents (small mesh tubes) in narrowed arteries of stroke patients.

During the study, patients will receive treatment with these blood-thinning medications while undergoing emergency procedures to restore blood flow to the brain. The doctors will monitor how well the stents stay open and check the patients’ recovery from stroke over several months. They will also carefully watch for any bleeding complications that might occur during or after the treatment.

Participants in the study will be assigned to receive either the inhaled medicine or the injectable medicine. After the procedure is completed, the amount of brain tissue damage, known as cerebral infarction, will be measured. This measurement is performed using an MRI, which is a specialized imaging test that uses strong magnets to create detailed pictures of the inside of the body. The evaluation of the brain area affected by the stroke will take place approximately 72 hours after the treatment.

The placebo used in this study consists of sodium chloride. To evaluate how well the treatments work, the size of the injured area in the brain will be measured using MRI, a medical imaging technique that uses magnets to create detailed pictures of the body. Specifically, the study looks at the growth of the area of dead brain tissue over a period of 72 hours. Other aspects of the study involve monitoring physical health, potential side effects, and changes in certain substances in the blood that relate to inflammation.

During the trial, participants will receive either tenecteplase or the standard of care via an intravenous bolus, which is a method of delivering medication directly into a vein in a single quick dose. The study will monitor how well patients recover and function over a period of time, specifically looking at their ability to perform daily activities 90 days after the event. The researchers will also observe for any potential side effects, such as symptomatic intracranial hemorrhage, which is a type of bleeding inside the brain that can occur following treatment.

One treatment approach involves thrombectomy, a procedure where doctors use specialized tools to physically remove the clot from the blocked artery. The other approach combines this procedure with intravenous thrombolysis, which is the administration of a clot-dissolving medication through a vein. In this study, the medication used for this process is tenecteplase. Participants will be assigned to receive either the combination of the medication and the procedure or just the procedure alone.

During the study, the effectiveness of the treatments will be observed by monitoring how well patients can perform daily activities and move independently. Doctors will also use imaging techniques like diffusion weighted imaging and fluid attenuated inversion recovery, which are special types of MRI scans used to look at the brain, to evaluate the extent of the brain injury. Safety will be monitored closely to check for any complications such as intracranial hemorrhage, which is bleeding inside the skull.

People in this study will have had their stroke within the past two weeks and will be taking either one or two antiplatelet medications as part of their treatment to prevent another stroke. The study will compare different approaches to selecting which antiplatelet medication works best for each person. During the study, participants will be followed for 12 months, with check-ups at 3 months and 12 months to see how well they are taking their medication and how well the medication is working. The study will also look at whether there are differences in how men and women respond to these treatments.

The main thing researchers will measure is how many people have another stroke, a heart attack, or die from heart-related causes within 12 months. They will also look at whether people have any bleeding problems, how well people stick to taking their medication, and how well people can function in their daily lives after 12 months. The study will examine genetic factors that might affect how people respond to these medications and will track all major health events that occur during the treatment period.

Patients in the study must have stroke symptoms that started within the past six hours, or in some cases with special imaging tests showing specific patterns in the brain, symptoms may have been present for a longer time or the exact time may be unknown. Before joining the study, patients will have brain imaging with either CT or MRI scans to make sure there is no bleeding in the brain. CT stands for computed tomography and MRI stands for magnetic resonance imaging, both of which are types of scans that create detailed pictures of the brain. Some patients may need additional specialized imaging tests that look at blood flow in the brain to check if they are suitable for the study.

During the study, patients will receive either tenecteplase or placebo as a single treatment. After treatment, doctors will monitor patients closely for any side effects, particularly any bleeding complications. The main assessment will occur ninety days after treatment, when doctors will evaluate how well patients have recovered and their ability to perform daily activities. Additional assessments will look at early improvement in stroke symptoms after twenty-four hours, quality of life, thinking abilities, and various safety measures including any bleeding events that may occur.

Participants in this study will be adults between 18 and 90 years old who have experienced a stroke within the past 24 hours. The treatment will be given over a period of 21 days. During the study, participants will have various health checks including physical examinations, blood tests, heart monitoring with an electrocardiogram, and measurements of vital signs such as blood pressure, heart rate, breathing rate, and body temperature. These checks will happen at different times during the study, including on days 1, 4, 21, and 90.

The main goal of the study is to measure how well participants recover from their stroke by day 90, which will be assessed using a scale called the modified Rankin Score that measures how well people can function in their daily activities. The study will also carefully track any side effects or unwanted reactions that participants may experience, including reactions at the injection site. Additional measurements will look at how independent participants are in performing daily activities, their neurological recovery, and whether they experience another stroke during the 90-day study period.

The purpose of this research is to determine if using these clot-dissolving medications leads to better recovery in stroke patients who are already taking blood-thinning medicines. The medications will be compared to standard care treatment to see if they can improve patients’ ability to perform daily activities after their stroke.

During the study, participants will receive either one of the clot-dissolving medications or standard care treatment. The treatment must be given within 4.5 hours of when stroke symptoms begin. Doctors will monitor patients’ recovery and check for any bleeding complications. Follow-up assessments will be conducted over 90 days to evaluate how well patients recover from their stroke.

The study will compare Cerebrolysin to placebo, with both being administered through infusion over a period of 21 days. During the treatment, patients will receive either the study medication or placebo mixed with sodium chloride solution. The maximum daily dose of Cerebrolysin will be 30 milliliters.

Patients will be monitored for a total of 90 days to assess how well their arm function improves after the stroke. The study will measure various aspects of recovery, including physical abilities, daily activities, and overall well-being. This is a double-blind study, which means neither the patients nor the healthcare providers will know who receives the actual medication or placebo during the treatment period.

The study will use several heart rhythm control medications including dronedarone hydrochloride, propafenone hydrochloride, amiodarone hydrochloride, and flecainide acetate. These medications are taken by mouth in tablet form and work to help regulate the heart’s rhythm. The maximum daily doses range from 300 to 800 milligrams, depending on the specific medication used.

During the study, patients will be monitored for various heart and blood vessel-related health events, including additional strokes, heart problems requiring hospitalization, and changes in heart function. The study will also track patients’ overall well-being, including their ability to perform daily activities, quality of life, and mental function. Participants will be followed for up to 24 months after starting treatment.

Participants in the study will receive either the JX10 treatment or a placebo, which is a substance with no active medication. The treatment is given as an infusion, meaning it is administered directly into the bloodstream through a vein. The study will compare the outcomes of those receiving JX10 with those receiving the placebo to see if there is a significant difference in recovery and symptom improvement.

The study will monitor participants over a period of time to assess their recovery and any potential side effects, such as the risk of bleeding in the brain, known as intracranial hemorrhage. The main goal is to see if JX10 can help patients have fewer or milder symptoms 90 days after their stroke. Participants will be closely observed to ensure their safety and to gather information on how well the treatment works.

Participants in the study will receive either the albumin treatment or a placebo. The treatment will be given through an infusion, which means it will be delivered directly into the bloodstream. The study will monitor the participants over a period of time to observe any changes in their condition, particularly focusing on the size of the brain lesion caused by the stroke and the overall recovery of the patient.

The study aims to gather information on the concentration of certain substances in the blood and urine, which can indicate the level of protection provided by the albumin. Additionally, the study will assess the participants’ recovery using various scales and tests, such as the Modified Rankin Scale (mRS), which measures the degree of disability or dependence in daily activities. The study will also track the participants’ health status up to 90 days after the treatment to evaluate long-term effects.

The purpose of the study is to evaluate how effective these CD34+ cells are in reducing the damage caused by the stroke. Participants in the study will receive the treatment within either 7 days or 20 days after their stroke. The study will monitor the size of the affected brain area over a period of three months to determine the treatment’s impact. The study will also assess various aspects of recovery, such as physical function, cognitive performance, and quality of life, using different scales and tests.

This trial is part of ongoing research to find better ways to treat ischemic stroke and improve recovery outcomes for patients. By exploring the potential benefits of CD34+ cells, researchers hope to develop new therapies that can help reduce the long-term effects of strokes and enhance the quality of life for those affected.

The purpose of the study is to compare the early improvement in neurological function between patients treated with intravenous thrombolysis (a treatment to dissolve clots) within 4.5 hours of stroke onset and those receiving the current standard care. Participants will be monitored for changes in their condition, including improvements in their ability to move and function, as well as any potential side effects. The study will also look at the overall recovery of patients over a period of 90 days.

Participants in the study will receive either the thrombolysis treatment or a placebo, and their progress will be closely observed by medical professionals. The trial aims to provide valuable insights into the effectiveness and safety of using thrombolysis in patients who have taken Factor Xa inhibitors, potentially leading to improved treatment options for those experiencing an acute ischemic stroke.

The study tests whether allopurinol, a medication that lowers uric acid levels in the blood, can help reduce the risk of cardiovascular events. Some participants will receive allopurinol tablets, while others will receive a placebo. The treatment will continue for approximately 5 years, during which participants will have regular check-ups to monitor their health status.

The main focus is to determine if allopurinol can prevent serious cardiovascular events such as heart problems, strokes, or the need for heart-related procedures. The study will also track other health changes, including heart function, blood vessel health, and the presence of long-COVID symptoms. Regular blood tests and heart examinations will be performed to monitor participants’ health throughout the study period.

The standard treatment in this study consists of blood-thinning medications such as Aspirine (containing acetylsalicylic acid) or Plavix (containing clopidogrel). The study will measure how well these different treatments prevent another stroke from occurring within one year after the first stroke. The study will also look at other important health outcomes such as serious bleeding events.

Participants in this study will be selected based on having high levels of a substance in their blood called MR-proANP, which is measured within three days of their stroke. The treatment period will last for 13 months, during which patients will take their assigned medication daily according to their doctor’s instructions.

The purpose of the study is to evaluate the effectiveness and safety of using alteplase in patients who have had an acute ischemic stroke and are on these blood thinners. The study is designed to compare the outcomes of patients receiving the treatment with those receiving a placebo. Participants will be randomly assigned to different groups, and neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This is known as a double-blind study. The trial will monitor patients over a period to assess their recovery and any changes in their condition.

Throughout the study, participants will receive regular assessments to track their progress. These assessments will help determine how well the treatment is working and if there are any side effects. The study aims to provide valuable information on whether the use of alteplase is a safe and effective option for patients with acute ischemic stroke who are on specific blood thinners. The findings from this study could potentially lead to improved treatment options for stroke patients in the future.

The purpose of the study is to evaluate how starting statin therapy affects the survival and quality of life of frail individuals aged 70 and above who have recently had a stroke or TIA. Participants will be randomly assigned to receive either a statin or a placebo. The study will follow participants for up to three years, with regular check-ins to monitor their health and any major cardiovascular events, such as heart attacks or strokes. The study will also assess participants’ quality of life and cognitive function, which refers to their ability to think, learn, and remember.

Throughout the study, participants will be asked to attend regular follow-up visits to track their progress. These visits will occur at 3, 6, 12, 18, and 24 months, with additional follow-up for those who join the study early. The study aims to provide valuable insights into the benefits and risks of using statins in older adults who have experienced a stroke or TIA, helping to guide future treatment decisions for this population.

Participants in the study will receive either the standard treatment with acetylsalicylic acid or the standard treatment plus mechanical thrombectomy. The study will monitor the participants’ recovery and health over a period of 90 days, using a scale called the modified Rankin Scale to assess their functional outcomes, which includes evaluating their ability to perform daily activities and their overall survival. The study will also look at changes in brain imaging results and any potential side effects, such as bleeding in the brain.

The trial aims to provide valuable insights into whether adding mechanical thrombectomy to the standard treatment can offer better recovery prospects for patients who have experienced an acute ischemic stroke due to a large vessel blockage. This research could potentially lead to improved treatment strategies and outcomes for individuals affected by this serious medical condition.

Participants in this study will have already received a treatment called thrombolysis, which involves using medication to dissolve blood clots. The study will observe how well dornase alfa works in improving blood flow in the brain after thrombectomy. The trial will involve monitoring the participants’ recovery and checking the blood flow in their brain using a special imaging technique called angiography, which provides a detailed view of the blood vessels.

The purpose of this study is to determine if dornase alfa can help improve the outcomes for patients who have had an ischemic stroke and are undergoing thrombectomy. The trial will last for a certain period, during which participants will be closely monitored for any changes in their condition and any side effects from the treatment. The results of this study could provide valuable information on the potential benefits of using dornase alfa in stroke treatment.

The purpose of this research is to determine if adding cangrelor to the standard mechanical thrombectomy treatment can improve recovery outcomes for stroke patients. The study involves patients who arrive at the hospital within 24 hours of their stroke symptoms beginning and who show specific patterns on their brain imaging scans.

During the study, participants will be divided into two groups. One group will receive the standard mechanical thrombectomy treatment plus cangrelor, while the other group will receive only mechanical thrombectomy. The maximum daily dose of cangrelor will be 150 milligrams, and the treatment will last for one day. Doctors will monitor patients’ recovery and brain function over three months to determine how well the combined treatment works.

The study involves giving some infants darbepoetin alfa, while others will receive a placebo, which is a substance with no active medication. The purpose is to compare the effects of darbepoetin alfa with the placebo to see if there is a difference in the extent of brain injury. The study will monitor the infants from the time of the stroke until they are 6-8 weeks old, looking at changes in brain tissue and growth. Additionally, the study will assess the infants’ development at 18 months of age, including their cognitive abilities and motor skills.

Participants in the study will be newborns who are at least 36 weeks old and have been diagnosed with PAIS through an MRI scan. The study will take place over several years, with the goal of finding a treatment that could potentially reduce or prevent the long-term effects of PAIS-related brain injury in newborns. By comparing the outcomes of those receiving darbepoetin alfa with those receiving a placebo, researchers hope to gather valuable information that could lead to improved treatments for this condition.

The medications used in the study include lidocaine (a local anesthetic), fentanyl (a pain medication), propofol (an anesthetic medication), rocuronium bromide (a muscle relaxant), and medical oxygen. These medications are given through a vein, except for oxygen which is inhaled. The study aims to determine which approach leads to faster treatment times from hospital arrival to blood flow restoration in the brain.

During the study, patients will receive either general anesthesia with the mentioned medications or sedation with oxygen through a high-flow nasal cannula while doctors perform the clot removal procedure. The doctors will monitor how quickly they can complete the treatment and track the patient’s recovery over time. They will also watch for any complications that might occur during or after the procedure.

The purpose of this study is to evaluate how effective and safe mepivacaine hydrochloride is in improving neurological symptoms that can occur after an ischemic stroke. These symptoms might include difficulties with movement, speech, or vision. Participants in the study will receive an injection of the medication, and researchers will observe any changes in their symptoms shortly after the injection.

Throughout the study, participants will be monitored to see if there is any improvement in their neurological symptoms, such as better language skills, motor skills, or visual abilities. The study aims to determine how many patients respond positively to the treatment with mepivacaine hydrochloride. This research could provide valuable insights into potential treatments for individuals who have suffered from an ischemic stroke.

The purpose of the study is to determine if adding intra-arterial thrombolysis can lead to better recovery in patients who have already had a successful initial treatment for their stroke. Participants in the study will receive either the additional treatment with Actilyse or no additional treatment after their initial stroke treatment. The study will monitor participants over a period of 90 days to assess their recovery and any changes in their ability to perform daily activities. The study aims to see if the additional treatment can help improve the overall recovery and reduce disability caused by the stroke.

Throughout the study, participants will undergo various assessments to track their progress. These assessments will include evaluations of their neurological function and overall health. The study will also monitor for any potential side effects or complications related to the treatment. The results of this study could provide valuable information on the effectiveness of intra-arterial thrombolysis in improving outcomes for patients who have experienced an ischemic stroke.

The purpose of the study is to evaluate how effective low doses of Colchicine and Ticagrelor are in reducing the chances of having another major vascular event, such as a stroke or heart attack. Participants in the study will take these medications over a period of time, and their health will be monitored to see if the medications help in preventing further issues. The study will also include a group of participants who will receive a placebo, which is a substance with no active medication, to compare the effects.

Throughout the study, participants will be asked to take the medications as directed and attend regular check-ups to monitor their health. The study aims to provide valuable information on whether these medications can be a beneficial treatment option for people at high risk of recurrent strokes or heart problems. The results could help in developing better prevention strategies for those with a history of ischemic stroke or related conditions.

The purpose of the study is to evaluate how effective Glenzocimab is when added to the standard treatment of mechanical thrombectomy. Participants in the study will receive either Glenzocimab or a placebo, in addition to the usual care. The study will monitor the participants’ recovery over a period of 90 days to assess their functional outcomes, which refers to how well they can perform daily activities after the treatment. The study will also look at the safety of Glenzocimab by checking for any side effects or complications that may arise during the treatment period.

Throughout the study, participants will undergo various assessments, including brain imaging and neurological evaluations, to track their progress. These assessments will help determine the effectiveness of Glenzocimab in improving recovery from an acute ischemic stroke. The study aims to provide valuable information on whether adding Glenzocimab to the current treatment can lead to better outcomes for patients who have experienced a stroke.

The purpose of this study is to determine if administering DNase can help lower the body’s immune response, which is often heightened after a stroke. This immune response is measured by looking at the levels of a specific protein in the blood called interleukin-1 beta (IL-1β). The study will compare the effects of DNase with a control treatment to see if there is a significant difference in the reduction of this protein.

Participants in the study will receive either the DNase treatment or a control treatment. The study will monitor the levels of interleukin-1 beta in the blood within 24 hours after the onset of stroke symptoms. The trial aims to provide insights into whether DNase can effectively reduce inflammation and improve outcomes for patients who have suffered an ischemic stroke. The study is expected to continue until the end of 2026.

The study will use three different medications: Urapidil, Phenylephrine Hydrochloride, and Labetalol Hydrochloride. These medications are administered intravenously, meaning they are given directly into a vein. Urapidil is used to lower blood pressure by relaxing blood vessels, Phenylephrine Hydrochloride is a cardiac stimulant that helps increase blood pressure, and Labetalol Hydrochloride works by blocking certain receptors in the body to lower blood pressure. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the actual medications.

The purpose of the study is to determine which method of blood pressure management provides the most benefit to patients after a stroke. Participants will be monitored for a period of up to three days, during which their blood pressure will be managed according to the assigned protocol. The study will assess the outcomes at 90 days after the treatment to see if there is an improvement in the patients’ recovery and overall health. This research aims to improve the treatment and recovery process for individuals who have experienced an acute ischemic stroke.

The main purpose of this study is to assess the safety of these stem cells when given to patients within the first four days after their stroke. The study is designed to be a double-blind trial, meaning neither the patients nor the researchers know who is receiving the stem cells and who is receiving a placebo. This helps ensure that the results are not biased. Participants will receive the treatment through an injection and will be monitored closely for any side effects or complications, such as worsening of the stroke, new strokes, or infections.

Throughout the study, patients will have regular check-ups to assess their recovery and any changes in their condition. These check-ups will include evaluations using the Modified Rankin Scale (mRS) and the NIH Stroke Scale, which are tools used to measure the level of disability and improvement after a stroke. The study will also look at various biochemical markers in the blood to gather more information about how the treatment is working. The trial is expected to continue until the end of 2026, with follow-up visits scheduled at several points over the next two years to track the long-term effects of the treatment.

Participants in the study will receive either Tirofiban or Aspirin as part of their treatment for an acute ischemic stroke that is caused by a tandem lesion, which involves blockages in both the neck and brain arteries. The study will monitor the rate of reocclusion and any instances of symptomatic bleeding. The trial will also evaluate the functional recovery of patients, aiming for a good outcome defined as a low score on a scale that measures disability, 90 days after treatment.

The study is designed to provide valuable information on the best treatment approach for patients with this type of stroke, potentially improving outcomes and reducing complications. Participants will be closely monitored throughout the study to ensure their safety and to gather data on the effectiveness of the treatments being tested.

The purpose of this research is to determine whether giving alteplase directly into the affected artery during mechanical thrombectomy can improve outcomes for stroke patients. The medication will be given through intraarterial injection, which means it is delivered directly into the blocked blood vessel while doctors are removing the clot.

During the study, participants will receive the standard mechanical thrombectomy procedure to remove the blood clot, with some patients also receiving alteplase through the artery. The treatment is given as a single dose during the procedure, and patients will be monitored afterward to assess their recovery from the stroke. The study will track how well patients recover their ability to perform daily activities and whether they experience any complications.

In addition to Glenzocimab, the study involves the use of GADOVIST, a contrast agent used in imaging tests to help visualize blood vessels and tissues more clearly. This agent is administered through an intravenous injection. The trial will also use a 0.9% sodium chloride solution, which is a common fluid used in medical settings. The main goal of the study is to determine if Glenzocimab can help patients achieve better functional outcomes, which means being able to perform daily activities more independently, three months after their stroke.

Participants in the study will receive either Glenzocimab or a placebo, and their progress will be monitored over a period of three months. The study will assess various outcomes, including the presence of any bleeding in the brain, the overall recovery of brain function, and the rate of survival. The trial aims to provide valuable information on whether Glenzocimab can be an effective treatment option for patients with ischemic stroke and a large ischemic core, potentially improving their quality of life after the stroke.

The medications being tested in this study are methylprednisolone and prednisolone. Methylprednisolone is administered intravenously, meaning it is given directly into a vein, while prednisolone is taken orally, in the form of tablets. These medications are being used in addition to the standard care, which includes treatments to prevent blood clots.

Participants in the study will receive either the steroid treatment or a placebo, alongside their usual care. The study will monitor changes in the severity of the arteriopathy over time, as well as any improvements in neurological function and the recurrence of strokes. The study will last for several months, with follow-up assessments to track the progress and outcomes of the treatment.

The purpose of the study is to determine if adding norepinephrine to the standard care for stroke patients can improve their recovery and functional independence after 90 days. Participants in the study will receive either the standard care alone or the standard care plus the norepinephrine infusion. The study will monitor the patients’ progress over a period of 90 days to assess their recovery and any changes in their condition.

Throughout the study, various aspects of the patients’ health will be evaluated, including their neurological improvement, any side effects from the treatment, and their overall well-being. The goal is to see if the use of norepinephrine can lead to better outcomes for patients who have suffered from an acute ischemic stroke, potentially offering a new approach to treatment that could enhance recovery and quality of life.

The purpose of the study is to determine the safety of multiple doses of the LT3001 Drug Product in individuals who have experienced an Acute Ischemic Stroke. Participants will receive either the drug or a placebo, and their health will be monitored to assess any side effects or adverse reactions. The study is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the actual drug or the placebo, to ensure unbiased results.

Participants in the study will be monitored for a period of time after receiving the treatment to observe any potential side effects. The main focus will be on identifying any adverse events that may be related to the treatment within 90 days of the first administration. This trial aims to provide valuable information on the safety and potential benefits of the LT3001 Drug Product for those affected by Acute Ischemic Stroke.